Cargando…

The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer

BACKGROUND: To evaluate the prognostic role of circulating fibrinogen-to-pre-albumin (FPR) in colorectal cancer (CRC) with different tumor locations, and its involvement in chemosensitivity and chemoresistance. PATIENTS AND METHODS: A total of 2917 eligible CRC patients from multiple centers were en...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Hou-Qun, Sun, Fan, Liao, Yu-Cui, Cai, Dan, Yang, Ying, Cheng, Xue-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243139/
https://www.ncbi.nlm.nih.gov/pubmed/34262615
http://dx.doi.org/10.1177/17588359211022886
_version_ 1783715711493865472
author Ying, Hou-Qun
Sun, Fan
Liao, Yu-Cui
Cai, Dan
Yang, Ying
Cheng, Xue-Xin
author_facet Ying, Hou-Qun
Sun, Fan
Liao, Yu-Cui
Cai, Dan
Yang, Ying
Cheng, Xue-Xin
author_sort Ying, Hou-Qun
collection PubMed
description BACKGROUND: To evaluate the prognostic role of circulating fibrinogen-to-pre-albumin (FPR) in colorectal cancer (CRC) with different tumor locations, and its involvement in chemosensitivity and chemoresistance. PATIENTS AND METHODS: A total of 2917 eligible CRC patients from multiple centers were enrolled in this prospective study, and 3 years follow-up was carried out to obtain the outcome of these patients. Circulating fibrinogen (Fib), pre-albumin (pAlb), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) were detected, and we calculated FPR according to the detected results. Kaplan–Meier curves, Cox proportional regression, time-dependent receiver operating characteristic curves, Harrell’s concordance index, calibration, and decision curves were used to investigate the role of FPR in predicting chemotherapy efficacy and prognosis of CRC patients. RESULTS: Our results showed that cancer bulk, its infiltrating depth, and the distal metastasis status of CRC determined circulating FPR levels. A high FPR was associated with a significantly inferior prognosis, while the outcomes of right-sided patients with stage III and IV CRC were worse than left-sided cases. Only FPR was found to be a reliable and independent prognostic factor for each stage of CRC. In addition, the prognostic FPR-contained nomograms were superior to the non-FPR nomograms and FPR in predicting the outcomes in both localized and metastatic CRC patients. The circulating FPR was significantly associated with chemotherapeutic efficacy in stage III and IV CRC patients. In particular, low-grade (FPR < 15) and medium-grade (15 ⩽ FPR < 20) FPR patients exhibited a complete response to chemotherapy and attenuated chemosensitivity, respectively; in contrast, high-grade inflammation (FPR ⩾ 20) conferred resistance to the treatment. CONCLUSION: Circulating FPR is a robust and independent prognostic factor, a simple and economically-friendly predictor of chemotherapy efficacy within cases of localized and metastatic CRC. FPR-contained nomograms are more effective in predicting the prognosis of these patients. FPR and the nomogram can be recommended for the evaluation of chemotherapy efficacy and to aid decision-making associated with the management of these patients.
format Online
Article
Text
id pubmed-8243139
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82431392021-07-13 The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer Ying, Hou-Qun Sun, Fan Liao, Yu-Cui Cai, Dan Yang, Ying Cheng, Xue-Xin Ther Adv Med Oncol Original Research BACKGROUND: To evaluate the prognostic role of circulating fibrinogen-to-pre-albumin (FPR) in colorectal cancer (CRC) with different tumor locations, and its involvement in chemosensitivity and chemoresistance. PATIENTS AND METHODS: A total of 2917 eligible CRC patients from multiple centers were enrolled in this prospective study, and 3 years follow-up was carried out to obtain the outcome of these patients. Circulating fibrinogen (Fib), pre-albumin (pAlb), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) were detected, and we calculated FPR according to the detected results. Kaplan–Meier curves, Cox proportional regression, time-dependent receiver operating characteristic curves, Harrell’s concordance index, calibration, and decision curves were used to investigate the role of FPR in predicting chemotherapy efficacy and prognosis of CRC patients. RESULTS: Our results showed that cancer bulk, its infiltrating depth, and the distal metastasis status of CRC determined circulating FPR levels. A high FPR was associated with a significantly inferior prognosis, while the outcomes of right-sided patients with stage III and IV CRC were worse than left-sided cases. Only FPR was found to be a reliable and independent prognostic factor for each stage of CRC. In addition, the prognostic FPR-contained nomograms were superior to the non-FPR nomograms and FPR in predicting the outcomes in both localized and metastatic CRC patients. The circulating FPR was significantly associated with chemotherapeutic efficacy in stage III and IV CRC patients. In particular, low-grade (FPR < 15) and medium-grade (15 ⩽ FPR < 20) FPR patients exhibited a complete response to chemotherapy and attenuated chemosensitivity, respectively; in contrast, high-grade inflammation (FPR ⩾ 20) conferred resistance to the treatment. CONCLUSION: Circulating FPR is a robust and independent prognostic factor, a simple and economically-friendly predictor of chemotherapy efficacy within cases of localized and metastatic CRC. FPR-contained nomograms are more effective in predicting the prognosis of these patients. FPR and the nomogram can be recommended for the evaluation of chemotherapy efficacy and to aid decision-making associated with the management of these patients. SAGE Publications 2021-06-28 /pmc/articles/PMC8243139/ /pubmed/34262615 http://dx.doi.org/10.1177/17588359211022886 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Ying, Hou-Qun
Sun, Fan
Liao, Yu-Cui
Cai, Dan
Yang, Ying
Cheng, Xue-Xin
The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title_full The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title_fullStr The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title_full_unstemmed The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title_short The value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
title_sort value of circulating fibrinogen-to-pre-albumin ratio in predicting survival and benefit from chemotherapy in colorectal cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243139/
https://www.ncbi.nlm.nih.gov/pubmed/34262615
http://dx.doi.org/10.1177/17588359211022886
work_keys_str_mv AT yinghouqun thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT sunfan thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT liaoyucui thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT caidan thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT yangying thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT chengxuexin thevalueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT yinghouqun valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT sunfan valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT liaoyucui valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT caidan valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT yangying valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer
AT chengxuexin valueofcirculatingfibrinogentoprealbuminratioinpredictingsurvivalandbenefitfromchemotherapyincolorectalcancer